An oral version of the GLP-1 drug semaglutide failed to significantly slow the disease's progression compared to a placebo.

We break down the current state of frontotemporal dementia, from bvFTD to PPA, and why 'promising' therapies are still far ...

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...

Top-line results from two large clinical trials by Novo Nordisk, the company behind Ozempic and Wegovy, found oral ...

Rutgers neuroscientist Peng Jiang and his neuroscience colleague Mengmeng Jin have made a discovery they say could reshape ...

News about Alzheimer's rose to the forefront in 2025, as the FDA approved the first diagnostic blood test and drugmakers ...

Researchers have discovered a natural mechanism that clears existing amyloid plaques in the brain and preserves cognitive ...

Chris Hemsworth's touching road trip with his father Craig, who has "early-stage Alzheimer's," is chronicled in a National ...

In people at risk for Alzheimer’s disease, researchers linked minimal to moderate physical activity to a 3-to 7-year delay in cognitive symptoms.

Alzheimer's disease affects about 250,000 older adults in Illinois. Experts and those who have had to take care of loved ones ...

A new study has identified three existing medications that could be repurposed to treat or prevent Alzheimer’s disease.